Is Migraine Treated Completely? A New Treatment Has Been Approached Successfully

Mohammedelhassan Ahmed Mohammedelhassan^1, and Mamoun Magzoub²

¹Neurologist, Medical Military Hospital, Omdurman, Sudan

²Faculty of Medical Laboratory Sciences, International University of Africa, Khartoum, Sudan

Cite this paper

Mohammedelhassan Ahmed Mohammedelhassan and Mamoun Magzoub. Is Migraine Treated Completely? A New Treatment Has Been Approached Successfully. American Journal of Clinical Medicine Research. 2017; 5(4):49-51. doi: 10.12691/AJCMR-5-4-2

Abstract

Objective: Migraine is one of the most frequent disabling neurological conditions and very bad headache with a major impact on the patient's quality of life. The objective of this study was to evaluate the effectiveness of Prednisolone in treating migraine. Methods: A cross sectional, hospital-based study was conducted. All patients (1020) were received Prednisolone 0.5 mg/kg/day for 7 days followed by tapering by 1 tablet (5 mg) every 7 days. The patients were followed minimally for six months after receiving treatment. Results: All patients responded to the treatment and all their associated symptoms disappeared. We think this approach is the best one for treating migraine. Conclusion: We think that our approach is the best one in treating migraine, so our recommendation is to use steroids (Prednisolone tablets, in a dose of 0.5 mg / kg/day for 7 days, followed by tapering by 1 tablet (5 mg) every 7 days) as a protocol for the treatment of migraine. The individual dose adjustment is required in certain cases. From this study we conclude that, firstly we can say we have got the answer of the big question: what is migraine. Secondly, we think we present a nice explanation of the vascular phenomenon associated with migraine. Number third, we introduce new common symptom associated with migraine. Lastly we introduce new and effective treatment for migraine.

Keywords

migraine, new, treatment, steroids

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Evers S, Fra JA, Frese PJ, Goadsby M, Linde A, May A, Sa´ndor PS. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. European Journal of Neurology 2009, 16: 968-981.
[2]	W Adams, Sanders S. Migraine: Prevent and Control Migraine Headaches. Conrad & Associates, LLC 2006; pp. 6.
[3]	Worthington I, Pringsheim T, Gawel1 MJ, Gladstone J, Cooper P, Dilli E, Aube M. Introduction to the Guideline, and General Principles of Acute Migraine Management. Can J neurol Sci. 2013; 40: Suppl. 3 - S4-S9.
[4]	Derry CJ, Derry S, and R Andrew Moore RA. Sumatriptan (oral route of administration) for acute migraine attacks in adults. The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 2.
[5]	Loder E. Triptan Therapy in Migraine. N engl j med 2010; 1: 363-70.
[6]	Johnston MM, Rapoport AM. Triptans for the management of migraine. drugs. 2010; 70: 1505-18.
[7]	Dodick d, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004; 44: 414-25.
[8]	Tepper SJ, Millson d. Safety profile of the triptans. Expert Opin drug Saf. 2003; 2: 123-32.
[9]	Eiland LS, Hunt MO. The use of triptans for pediatric migraines. Paediatr Drugs. 2010; 12(6): 379-89.
[10]	Kelly NE, Tepper DE. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache. 2012; 52(3):467-82.
[11]	Deborah Tepper. Episodic Acute Migraine Treatment Headache: The Journal of Head and Face Pain. American Headache Society Published by JohnWiley & Sons, Inc 2014.
[12]	Marmura MJ, Silberstein SD, Schwedt TJ. The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies. Headache 2015; 55: 3-20.
[13]	Edvinsson L. The Trigeminovascular Pathway: Role of CGRP and CGRP Receptors in Migraine. Headache the Journal of Head and Face Pain 2017; 57: 47-55.
[14]	Mohammedelhassan MA, Mohammedelhassan YA, Mohamed MM. Anew sign has been discovered as the predictor of Allergic and Autoimmune diseases. Kassala University Journal 2016; (8 & 9): 218-226.